Launched on June 19, 2006, the First Trust NYSE Arca Biotechnology ETF (FBT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the ...

Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their ...

Insider buying matters in every industry, but it carries a special weight in biotechnology. In most businesses, management has a reasonably clear view of sales trends, margins, customer demand, and ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Jonathan Faison first started exploring the biotech space a decade ago. He emphasizes a focus on preserving capital by limiting position sizes and picking stocks that have multiple "irons in the fire" ...

Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech: “These are growth stocks where you don’t have to worry about disruption ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

2022 has been a terrible, horrible, no good, very bad year for biotech. The industry has suffered from the broader market environment and from some forces specific to biotech. Overall, investors have ...

HudsonAlpha Institute's HOPE-AD study offers Alzheimer's risk assessment, revealing proactive steps high-risk individuals can ...